Paladin Labs receives approval for Valtaxin

Paladin (TSE:PLB) received Canadian marketing approval for Valtaxin valrubicin, a chemotherapeutic anthracycline derivative, for intravesical therapy of refractory carcinoma in situ (CIS) of the bladd...